The 2025 PDA Board of Directors: A Diverse Range of Interests and Expertise

PDA today released the names of its 2025 Board of Directors following fall elections by the membership. The sixteen directors represent pharmaceutical/biopharmaceutical businesses of all sizes and areas of competency across the United States, Europe and Asia.

"I congratulate new directors Marcia Baroni and Morten Monk, who will serve in 2025 and 2026," said Glenn Wright, PDA President and CEO. "I offer my deepest gratitude to Mirko Gabriele and Stephan Kruse for completing their service to the Board at the end of 2024."

The complete 2025 Board of Directors and Officers will be composed of the following volunteers:

Officers

• Chairs: Anil Sawant, Merck & Co.
• Chair-Elect: Melissa Seymour, Eli Lilly
• Treasurer: Emma Ramnarine
• Secretary: Bettine Boltres, West Pharmaceutical Services
• Im. Past Chair: Sue Schniepp, Regulatory Compliance Associates Inc.

Directors

• Marcia Baroni, Emergent BioSolutions Inc
• Lisa Bennett, LB Consulting Australia Pty Ltd
• Cristiana Campa, PhD, GSK
• Andrew Chang, PhD, Novo Nordisk
• Cylia Chen-Ooi, MA, Amgen
• Marc Glogovsky, ValSource Inc.
• Andrew Hopkins, Lachman Consultants
• Ivy Louis, MBA, Vienni Training & Consulting LLP; Eduoriens Skill Development LLP
• Amy McDaniel, PhD, Bristol Myers Squibb
• Morten Munk FUJIFILM Diosynth Biotechnologies
• Brigitte Reutter-Haerle, Vetter Pharma
• Osamu Shirokizawa, Life Scientia Ltd.